Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers
I'm PortAI, I can summarize articles.
Precipio's Q3 2025 revenue increased by 30% year-over-year to $6.8 million, driven by new customer acquisitions. The company achieved a positive adjusted EBITDA, improving by over $500,000 from Q2, and generated $285,000 in cash from operations. Revenue growth was attributed to a 20% increase in pathology services and a 16% rise in the product division. The company expects gross margins to approach 50% due to operational efficiencies and financial discipline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments